{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04064190",
            "orgStudyIdInfo": {
                "id": "MP-VAC-202"
            },
            "organization": {
                "fullName": "MedPacto, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition",
            "officialTitle": "A Phase 2 Study of TGF-\u03b2 Inhibition (Vactosertib) With Anti-PD-L1 (Durvalumab) in Patients With Advanced or Recurrent Urothelial Carcinoma Failing to Achieve Response With Checkpoint Inhibition",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "vactosertib-with-durvalumab-in-urothelial-carcinoma-failing-checkpoint-inhibition"
        },
        "statusModule": {
            "statusVerifiedDate": "2021-09",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-10-15",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-08-15",
            "studyFirstSubmitQcDate": "2019-08-19",
            "studyFirstPostDateStruct": {
                "date": "2019-08-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2021-09-22",
            "lastUpdatePostDateStruct": {
                "date": "2021-09-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "MedPacto, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "AstraZeneca",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1/PD-L1 based regimens",
            "detailedDescription": "This is a Phase 2, open-label, non-randomized, two-cohort multi center study with a safety run-in of 6 patients in Cohort 1. It is anticipated that a total of 48 patients will be enrolled.\n\nDurvalumab will be administered with the standard regimen of 1500 mg intravenously (IV) every four weeks. Vactosertib will be administered at a dose of 300 mg PO BID for 5 days per week All treatment will be administered up to two years and the trial is anticipated to be completed over a period of 36 months."
        },
        "conditionsModule": {
            "conditions": [
                "Urothelial Carcinoma Recurrent",
                "Advanced Urothelial Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Phase 2, open label, non randomized single arm study with two cohorts and a safety run-in for first six patients",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Vactosertib+Durvalumab",
                    "type": "EXPERIMENTAL",
                    "description": "Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.",
                    "interventionNames": [
                        "Drug: Vactosertib(TEW-7197)/ Durvalumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Vactosertib(TEW-7197)/ Durvalumab",
                    "description": "Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks",
                    "armGroupLabels": [
                        "Vactosertib+Durvalumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall Response Rate",
                    "description": "ORR by RECIST version 1.1",
                    "timeFrame": "12months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to Tumor Response",
                    "description": "TTR by RECIST version 1.1 and iRECIST",
                    "timeFrame": "Overall study period up to 3years"
                },
                {
                    "measure": "Best Response",
                    "description": "Best response (percent of tumor shrinkage) by RECIST version 1.1 and iRECIST",
                    "timeFrame": "Overall study period up to 3years"
                },
                {
                    "measure": "Duration of Response",
                    "description": "DoR by RECIST version 1.1 and iRECIST",
                    "timeFrame": "Overall study period up to 3years"
                },
                {
                    "measure": "Progression Free Survival",
                    "description": "PFS by RECIST version 1.1 and iRECIST",
                    "timeFrame": "6-month/ 12-month"
                },
                {
                    "measure": "Overall survival",
                    "description": "OS by RECIST version 1.1 and iRECIST",
                    "timeFrame": "12month"
                },
                {
                    "measure": "Tumor-specific immune responses",
                    "description": "tumor-specific immune responses within on-therapy biopsies measured by increased T cell infiltration and increased IFN-\u03bb signature. and the correlation with outcome as measured by ORR, TTR, DoR, PFS and OS",
                    "timeFrame": "Overall study period up to 3years"
                },
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]",
                    "description": "To assess safety and tolerability of vactosertib administered concurrent with Durvalumab in patients with urothelial carcinoma failing checkpoint inhibition",
                    "timeFrame": "Overall study period up to 3years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrollment\n2. Histologically or cytologically documented locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra.\n3. Prior anti-PD-(L)1 treatment.\n4. Measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or MRI.\n5. Recurrent disease after any prior platinum-based chemotherapy regimen or ineligible for platinum therapy.\n6. Adequate organ and marrow function as defined\n7. Must have a life expectancy of at least 12 weeks.\n8. Body weight \\> 30 kg\n\nExclusion Criteria:\n\n1. History of allogeneic organ transplantation.\n2. Active or prior documented autoimmune or inflammatory disorders\n3. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure .\n4. History of another primary malignancy\n5. History of leptomeningeal carcinomatosis.\n6. History of active primary immunodeficiency.\n7. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen \\[HBsAg\\] result), hepatitis C, or human immunodeficiency virus .\n8. Any unresolved toxicity NCI CTCAE Grade \u2265 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sunjin Hwang, MD",
                    "role": "CONTACT",
                    "phone": "+82 2 6938 0206",
                    "email": "sunjin.hwang@medpacto.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lawrence Fong, MD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California San Francisco",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Larry Fong, Dr",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Roswell Park Comprehensive Cancer Center",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gurkamal Chatta, Dr.",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002295",
                    "term": "Carcinoma, Transitional Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "asFound": "Urothelial Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "asFound": "Urothelial Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T929",
                    "name": "Camurati-Engelmann Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000613593",
                    "term": "Durvalumab"
                },
                {
                    "id": "C000590371",
                    "term": "Vactosertib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M272500",
                    "name": "Durvalumab",
                    "asFound": "Pancreatic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M96450",
                    "name": "Vactosertib",
                    "asFound": "JAK2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}